(Total Views: 118)
Posted On: 02/15/2024 3:05:45 PM
Post# of 43997
$RENB Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
Renovaro Biosciences Inc.
Renovaro Biosciences Inc.Renovaro Biosciences Inc.
Renovaro Biosciences Inc.
A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.
Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
Cyclomics’ 4th generation liquid biopsy genomics platform is the first truly “Omni-Omic” blood test ready for AI application.
GEDiCube’s award-winning AI is developing high-performance biomarker panels for 13 different cancers.
GEDiCube’s partnership with NVIDIA’s Inception program will help expand to multi-modal capabilities by adding imaging.
Renovaro Biosciences Inc.
Renovaro Biosciences Inc.Renovaro Biosciences Inc.
Renovaro Biosciences Inc.
A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.
Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
Cyclomics’ 4th generation liquid biopsy genomics platform is the first truly “Omni-Omic” blood test ready for AI application.
GEDiCube’s award-winning AI is developing high-performance biomarker panels for 13 different cancers.
GEDiCube’s partnership with NVIDIA’s Inception program will help expand to multi-modal capabilities by adding imaging.
(0)
(0)
